NewcelX Stock (NASDAQ:NCEL)

Financials Chart

Previous Close

$3.36

52W Range

$1.83 - $30.80

50D Avg

$2.87

200D Avg

$8.80

Market Cap

$1.51M

Avg Vol (3M)

$39.77K

Beta

1.00

Div Yield

-

NCEL Company Profile

NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CH

Employees

11

IPO Date

Oct 24, 2025

Website

NCEL Performance

NCEL Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-4.38M	$-11.81M	$-15.48M
Net Income	$-1.98M	$-12.17M	$-16.50M
EBITDA	$-3.63M	$-11.80M	$-15.47M
Basic EPS	$-26.30	$-3.20	$-8.40
Diluted EPS	$-26.30	$-3.20	$-8.40

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
OCEA	Ocean Biomedical, Inc.
SRZN	Surrozen, Inc.
CELU	Celularity Inc.
PRE	Prenetics Global Limited
CERO	CERo Therapeutics Holdings, Inc.
BACK	IMAC Holdings, Inc.
SABS	SAB Biotherapeutics, Inc.
NUWE	Nuwellis, Inc.
KTTA	Pasithea Therapeutics Corp.